Significant angiogenesis is one of the malignant features in astrocytomas. Cotransfactor Yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ) is a major regulator of embryonic angiogenesis, in which it plays an essential role in vascular tip cell migration, blood vessel formation, and vascular barrier maturation. We quantified TAZ expression on blood vessels and parenchyma of astrocytomas of varying malignancy to investigate its role in tumor angiogenesis. Replicating others' findings, we observed that TAZ is expressed in tumor cells but also in vascular cells. TAZ expression in both cell types was correlated with malignant grade. Immunofluorescence staining for TAZ, smooth muscle actin, and CD31 verified that TAZ-expressing vascular cells are endothelial cells, not pericytes. Analysis of blood vessel density using CD31 immunolabeling revealed that endothelial cell TAZ immunoreactivity was positively correlated with blood vessel density. MRIacquired tumor blood perfusion measurements in 12 pre-excision glioblastomas and subsequent postexcision TAZ staining supported that TAZ immunoreactivity-blood vessel density correlation with blood perfusion. In glioblastoma, TAZ staining was denser in glomerular neovascularization than that in the thin-walled neovascularization. TAZ expression was also correlated with vascular endothelial growth factor 2 (VEGFR2) immunoreactivity on endothelial cells. Our results indicate that VEGFR2/TAZ signaling pathway plays an important role in angiogenesis in astrocytomas.
INTRODUCTION
Diffuse astrocytomas, in particular glioblastoma, are the most common gliomas. According to the World Health Organization (WHO) classification of gliomas of the central nervous system, this kind of neoplasm is histologically graded by cytological atypia, mitotic activity, microvascular proliferation, and/or necrosis (1) . These features are indicative of the malignant potential of the tumor in terms of invasion and growth rate. Diffuse astrocytic tumors are classified as WHO grades II-VI as follows: Diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (WHO grade III), and glioblastoma ([GBM]; WHO grade IV).
The GBM is a highly malignant primary brain tumor that occurs mostly in adults. The presence of microvascular proliferation is a histopathological hallmark of GBM. Among all the types of human tumors, GBM is maximally vascularized. The current standard therapy for GBM is a combination of surgery, fractionated radiotherapy, and chemotherapeutic treatment with temozolomide, a DNA alkylating agent. However, this therapy offers only a median survival time of 15 months (2) . Given the role of angiogenesis in astrocytoma growth and malignancy, therapy advancements will depend on gaining a better understanding of factors regulating angiogenesis (2) .
Vascular endothelial growth factor (VEGF) plays a major role in angiogenesis. The VEGF was first discovered in 1983, when it was reported to promote vascular permeability (3) . It was also speculated to be one of the key regulators of angiogenesis, stimulating proliferation, chemotaxis, survival, and permeability of endothelial cells (4) . VEGF release is stimulated by hypoxia-inducible factors, which are activated when blood supply is insufficient, for instance, in the case of fast-growing cancers (5) .
Organogenesis shares some features with neoplasms. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are related transcriptional coactivators that regulate organ growth (6) . Overexpression of YAP/TAZ has also been shown to be involved in the proliferation, progression, and metastasis of various cancers (6) . Their activity is mainly regulated by the Hippo pathway (6) . The role of these 2 factors in cancer may be related to the finding that YAP/TAZ are major regulators of embryonic angiogenesis (4) . YAP/TAZ mediate VEGF/VEGFR2 signaling via a specific transcriptional program, which is essential for vascular tip cell migration (7) , blood vessel formation (4) , and vascular barrier maturation (8) in sprouting angiogenesis of the retina and brain during embryonic development. YAP/ TAZ are involved in morphogenesis, polarization, and migration of tip endothelial cells and proliferation of stalk endothelia in the growing vascular front, where they regulate actin cytoskeleton rearrangement, cell progression, and metabolism (9, 10) . If these processes proceed in an uncoordinated way, pathological angiogenesis will unfold since VEGF is also overexpressed in GBM (11) .
These observations prompted us to hypothesize that TAZ acts as a downstream signaling molecule of VEGF, which in turn promotes aberrant angiogenesis in astrocytomas when deregulated. To find support for this hypothesis, correlative evidence of YAP/TAZ expression and increased blood vessel density in human astrocytomas would be useful. Using large numbers of human astrocytoma samples, we evaluated whether TAZ expression is positively associated with tumor malignant grade and vascular density in human astrocytomas. We found that TAZ expression is positively correlated with malignant grade in both astrocytoma tumor cells and endothelial cells. In endothelial cells, TAZ expression was positively correlated with the density of blood vessels. In GBM, TAZ is more densely distributed in the glomerular neovascularization than in the thin-walled neovascularization. TAZ expression was also positively correlated with VEGFR2 expression in endothelial cells. Thus, the current results provide evidence for the critical role of VEGFR2/TAZ signaling in endothelial proliferation in astrocytomas.
MATERIALS AND METHODS

Tumor Specimens, Classification, and Patient Characteristics
We conducted a retrospective study of human astrocytoma samples from the Department of Pathology, Huashan Hospital, affiliated to Fudan University, Shanghai, China from 2010 to 2011. Two experienced neuropathologists made the diagnosis and graded the malignancy of the astrocytoma samples according to criteria established by the WHO (1). We obtained formalin-fixed, paraffin-embedded astrocytoma samples from 187 individuals. Of these, 30 were diffuse astrocytomas (grade II); 29 were anaplastic astrocytomas (grade III); and 128 were GBM (grade IV). Diffuse astrocytomas were also classified as low-grade gliomas (LGG), whereas anaplastic astrocytomas and GBM were classified as high-grade gliomas (HGG) (1) .
The median age of the patients from which the tumors were excised was 50.85 6 15.19 years (range 7-79 years), with a male-to-female ratio of 1.83 (male: 121 cases; female: 66 cases). The Ethics Committee of Fudan University approved the procedures associated with the acquisition of samples from human subjects, and written informed consent was obtained from patients to use their samples in further research. All procedures for obtaining and handling human tissue samples were consistent with the Helsinki Declaration 
Pre-excision MRI Analysis of Tumor Blood Perfusion
In order to quantify blood perfusion of the tumors, 12 patients with pathologically confirmed GBM (6 males, 6 females) were also studied in pre-excision experiments. Their mean 6age was 45 6 8 years (range 23-74 years). All patients underwent conventional head MRI using dynamic susceptibility contrast (DSC)-MRI within 1 week before excision surgery. No patient in the study received any other treatment (radiotherapy, chemotherapy) at imaging or before surgery. All the MRI data were used to guide the patients' further clinical treatment and follow-up. All these procedures were approved by Fudan University Institutional Review Board, and informed written consent was obtained from all patients.
Immunohistochemistry
Formalin-fixed, paraffin-embedded astrocytoma sections (4-lm thickness) were used to determine TAZ, CD31, and VEGFR2 distributions. Sections were prepared for immunohistochemistry (IHC) staining using the labeled streptavidin-biotin method (Dako-Agilent Technologies, Inc., Santa Clara, CA). After deparaffinization of mounted sections, endogenous peroxidase activity was blocked by incubating the sections in a 3% hydrogen peroxide (H 2 O 2 )-methanol solution for 10 minutes at room temperature. Antigen retrieval was then performed with 10 mM citrate buffer (pH 6.0) for 10 minutes at 95-100 C. Then, the slides were blocked for nonspecific staining with 10% normal goat serum (Abcam, Cambridge, UK) in phosphate-buffered saline for 20 minutes at room temperature. The sections were then incubated with the following primary antibodies: Rabbit polyclonal anti-TAZ (cat# HPA007415; dilution, 1:400; Sigma-Aldrich, St Louis, MO); rabbit polyclonal anti-CD31 (cat# ab28364; dilution, 1:50; Abcam); and rabbit monoclonal anti-VEGFR2 (cat# 55B11; dilution, 1:200, Cell Signaling Technology, Beverly, MA). Immunoreactive elements were visualized with a rabbit/ mouse peroxidase/3,3 0 -diaminobenzidine (DAB) EnVisio Detection kit (cat# GK500705; Dako-Agilent Technologies, Inc.) containing the secondary antibody and the DAB chromogen. Staining was done according to the manufacturer's protocol; sections were counterstained with hematoxylin to show cell nuclei. Sections incubated without primary antibody were used as negative controls.
Semiquantitative Analysis of TAZ, VEGFR2, and CD31 Immunoreactivity
To quantify TAZ and VEGFR2 immunoreactivity, we calculated immunoreactivity scores (IRS) based on staining intensity and the percentage of positively labeled cells in stained sections. The fraction (staining percentage [SP]) of positively stained cells was estimated and scored as follows: 0, 0%-1%; 1, 2%-25%; 2, 26%-50%; 3, 51%-75%; and 4, 75%-100%. The staining intensity (SI) was subjectively scored as follows: 0, no staining; 1, weak but definite; 2, moderate; and 3, intense. IRS was calculated using the following formula: IRS ¼SP ÂSI. The total score was 12, and the range was from 0 to 12.
To quantify blood vessel density in tumors resected from patients (see below), we processed GBM tissue samples for IHC staining against CD31 using the procedures described above. Five highly CD31-positive areas (173 lm 2 each) were selected from each sample for quantification. Light microscopy was used, and images were acquired using a chargecoupled device camera. For analysis and measurements, we used IMT i-Solution images-processing measurement and analysis software (IMT i-Solution, Inc., Burnaby, BC, Canada). The percentage of staining in each field was obtained by dividing the CD31-positive area by the calculated area of tumor vessels (lm 
Fluorescent Multiplex Immunofluorescence Staining
For multiple-antigen fluorescence staining against TAZ, CD31, and smooth muscle actin (SMA), we used an Opal 4-Color Fluorescent IHC Kit (MEL794001kt; PerkinElmer, Inc., Woburn, MA). Anti-SMA antibody (see below) was used to label pericytes. Paraffin-embedded tumor sections were mounted onto slides and deparaffinized using a standard method. After antigen retrieval and blocking, the first primary antibody (rabbit polyclonal anti-TAZ; cat# HPA007415; dilution, 1:1000; Sigma-Aldrich) was applied to the slides for 1.5 hours at room temperature, followed by application of HRP-conjugated mouse or rabbit secondary antibodies and Opal working solution (Cy5 fluorophore for TAZ) for 10 minutes at room temperature. Then, the tissue sections were subjected to antigen retrieval by microwaving the slides for 15 minutes to strip the antibodies. Subsequently, the process was repeated using the second primary antibody (rabbit polyclonal anti-CD31; cat# ab28364; dilution, 1:250; Abcam) and the third primary antibody (mouse monoclonal anti-SMA; cat# ZM-0003, dilution, 1:500; OriGene Biotech Co., Ltd., Wuxi, China) using different Opal fluorophores (FITC for anti-CD31 and Cy3 for anti-SMA). Finally, the slides were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) for 5 minutes at room temperature to label all cell nuclei. Images were acquired using a Mantra Quantitative Pathology Workstation (CLS140089; PerkinElmer Inc., Waltham, MA).
MRI Examination and Processing
Twelve GBM samples had presurgical MRI blood perfusion data of the tumor. MRI examination was done with a 3 T Siemens Viero MRI scanner (Siemens, Erlangen, Germany) using an 8-channel head coil. Raw perfusion data were transferred to an image-processing workstation (Syngo MR B14 version; Siemens), and image-processing software (Syngo Volume Perfusion CT Neuro; Siemens) was used to analyze the data. Local cerebral perfusion pressure is known to be a primary factor controlling cerebral circulation. Previous studies indicate that the ratio of cerebral blood flow (CBF) to cerebral blood volume (CBV) can be used as an index of the local cerebral perfusion pressure (13) . In this study, we also used the CBF and CBV ratios to quantify the blood flow in the GBM tissue. CBF and CBV maps were obtained with dynamic susceptibility perfusion (DSC)-MRI.
Two experienced radiologists (Dr D.Y. Geng and Dr J.B. Wen) were double-blinded while evaluating the blood perfusion parameters. The highest CBV and CBF signals in tumor parenchyma in T1-weighted images (T1WI) or the enhanced areas in T2-weighted images (T2WI) were marked as regions of interest (ROI). Each ROI contained 15-20 voxels. The average CBV or CBF values for all voxels in the ROI were recorded as CBV and CBF values. The ROIs avoided hemorrhagic, cystic, necrotic areas, and normal vessels within the lesion (according to the T2WI and enhanced T1WI images). For standardization, we selected the corresponding ROI in normal control white matter of the contralateral hemisphere of each patient, and measured and recorded the mean CBV or CBF in that ROI. The corresponding CBV and CBF ratios were then calculated as follows: CBV ¼ CBV tumor / CBV control and CBF ¼ CBF tumor /CBF control .
Statistical Analyses
Statistical analyses were performed using the statistical software GraphPad Prism, version 7.0 (La Jolla, CA). We used unpaired t-tests or one-way analysis of variance, followed by Scheffe's post hoc tests. When appropriate, we used v 2 tests. Linear correlation analysis was used to examine the association between TAZ IRS and CD31 and the other quantification parameters of stained astrocytoma samples. p < 0.05 was considered to indicate a statistically significant difference. Data are expressed as means 6standard error of the mean (SEM).
RESULTS
TAZ Immunoreactivity in Parenchyma and Blood Vessels of Astrocytomas Is Positively Correlated With WHO Malignant Grade
Consistent with the literature, we observed that astrocytoma cells expressed TAZ in cell nuclei and cytoplasm (8) . For the 187 astrocytoma samples, the degree of TAZ expression in parenchyma tumor cells was positively correlated with the malignancy grade of the tumor (Fig. 1A) . That is, grade III and IV tumors had a significantly higher percentage (65.5% and 73.4%, respectively) of TAZ-positive cells than did Grade II tumors (40.0%) (Fig. 1A) .
We also observed TAZ immunoreactivity on blood vessels of astrocytomas. This was also positively correlated with WHO tumor malignancy grade. Grade III and IV astrocytomas had significantly more TAZ blood vessels positive cases (79.3% and 89.1%, respectively) than did Grade II tumors (43.3%) (Fig. 1B) . Higher WHO malignancy grades had significantly more intense TAZ-positive staining in blood vessels.
In order to verify whether isocitrate dehydrogenase (IDH) status, which has been required by the WHO classification of gliomas as the diagnostic and prognostic molecular marker of glioma (1), has influence on TAZ expression of blood vessels, we selected paraffin-embedded sections of 30 grade II astrocytoma samples (15 IDH1 wild-type and 15 mutated cases separately) and 30 grade III astrocytoma samples (15 IDH1 wild-type and 15 mutated cases separately) to do TAZ immunostaining. We found TAZ IRS scores of blood vessels in grade II astrocytomas with or without IDH1 mutation were 0.9330 6 2.2740 or 0.6667 6 0.8165 (p ¼ 0.557), while in grade III astrocytomas with or without IDH1 mutation, they were 2.8670 6 3.2260 or 2.5000 6 2.3450 (p ¼ 0.7309). According to this data, it seems that the difference of TAZ expression on blood vessels is due to malignant Table S1 and Fig. S1 ). In some samples, TAZ appeared to be expressed in both tumor parenchyma cells and blood vessels, while in some samples it appeared to be expressed either only in tumor parenchyma cells or only in blood vessels (Fig. 1C-F) . A modest positive correlation was observed between the intensity of TAZ immunoreactivity in endothelial cells and tumor parenchyma cells (r ¼ 0.2111, p ¼ 0.0106). This indicates that, in addition to the role of tumor cell proliferation, TAZ may also be involved in astrocytoma angiogenesis.
No TAZ-positive staining was observed in neurons, glial cells, or blood vessels in normal-appearing brain tissue beyond the tumor margins.
TAZ IRS in Endothelial Cells Is Associated With Glomeruloid-Type Blood Vessel Proliferation in GBM
In GBM, microvascular proliferation typically appears as glomeruloid tufts of multilayered mitotically active endothelial cells, together with pericytes (1). These morphologically abnormal vessels are a hallmark of GBM, and they often coexist with more normal-appearing thin-walled tumor blood vessels (1). The proliferation phenotypes of glomeruloid and thin-walled blood vessels of GBM are shown in Figure 2A , B, respectively. Overall, we found that TAZ IRS was greater in glomeruloid tufts (6.53 6 0.39) than in thin-walled blood vessels(4.48 6 0.33) with a p value less than 0.001 (Fig. 2C) . By using anti-CD31 antibody to label endothelial cells and anti-SMA antibody to label pericytes, we found that TAZ IRS appeared to be localized primarily over the nuclei of CD31-positive endothelial cells but not over SMA-positive pericytes (Fig. 2D-G) .
TAZ IRS Is Greater in High-Grade Tumors and Is Associated With Blood Vessel Density and Blood Perfusion in GBM
To further examine the relationship between TAZ IRS and the vasculature of astrocytomas, we calculated IRS values for TAZ on blood vessels in the 187 astrocytoma samples. This score is based on TAZ staining intensity and distribution in TAZ-immunostained sections (see "Materials and Methods"). Representative photomicrographs showed TAZ immunostaining intensity varied from negative to strongly positive (Fig. 3A-D) .
For semiquantification of TAZ distribution, we first categorized each of one the 187 astrocytoma samples as either a low-grade astrocytoma or a high-grade astrocytoma (1), and then calculated the IRS scores for blood vessel TAZ staining in the samples. On average, HGG tumors had significantly higher TAZ IRS values(5.26 6 0.26) than LGG tumors (0.96 6 0.34) with a p value less than 0.001 (Fig. 3E) . Next, to obtain the blood vessel density, we stained the samples for CD31, a specific marker for vascular endothelial cells. Microvessel density was higher in HGG samples (1.88 6 0.14) than in LGG samples (0.88 6 0.22) (Fig. 3F) . TAZ IRS values were positively correlated with microvessel density (r ¼ 0.3030, p < 0.001).
Next, we sought to determine whether TAZ IRS is correlated with blood perfusion in astrocytomas in vivo. For the 12 patients with GBMs who had tumor blood perfusion by MRI before surgical excision, we also did TAZ staining on their paraffin-embedded tissues. We confirmed that TAZ IRS in the blood vessel cells was positively correlated with the tumors' CBF (Fig. 3G, H) , whereas TAZ IRS was not correlated with the tumors' CBV. These results further support the finding that TAZ is involved in angiogenesis within astrocytomas and is associated with blood perfusion in the tumor.
TAZ IRS Is Positively Correlated With VEGFR2 Immunoreactivity on Endothelial Cells
VEGF plays an important role in angiogenesis. VEGF has multiple isoforms, due to alternative splicing or proteolytic cleavage, and is characterized by different receptor-binding and matrix-binding properties (14) . Yu et al concluded that VEGF/VEGFR2 signaling promotes the nuclear localization of YAP through the canonical Hippo pathway (15) .
We assessed VEGFR2 immunoreactivity in astrocytoma samples. In serial sections immunolabeled for TAZ and VEGFR2 (Fig. 4A, B) , we observed that TAZ IRS appeared to be closely associated with VEGFR2 IRS in endothelial cells. We divided samples into TAZ IRS high (IRS >4) and low (IRS 4) groups. We found that the percentage of VEGFR2-positive samples in TAZ high IRS group was 64%, and that in TAZ low IRS group was 25% (p < 0.01) (Fig. 4C, D) . Their positive correlation suggests that VEGFR2/TAZ signaling may play a critical role in astrocytoma angiogenesis.
DISCUSSION
Elevated YAP/TAZ expression, or nuclear enrichment of YAP/TAZ, plays a critical role in the proliferation of a variety of cancers, including liver, breast, lung, colon, and ovary (16) . Moreover, the expression of TAZ in glioma cells is associated with the epithelial-mesenchymal transition of tumor cells, which in turn is associated with the invasive proliferation of the glioma, and poor prognosis resistance to radiation treatment (17) . In the present study, we found evidence that supported our hypothesis that TAZ seems to act as a downstream signaling molecule of VEGF. Specifically, TAZ immunoreactivity was more intense on CD31-positive endothelial cells of higher-grade tumors and was closely associated with VEGFR2-immunostained vessels in the tumors. For the 12 patients who had blood perfusion imaging of MRI-identified GBMs before excision, we confirmed that TAZ IRS in the excised tumor parenchyma cells and blood vessel cells was positively correlated with pre-excision CBF of the tumors. Thus, our results indicate that dysregulated VEGFR2/TAZ signaling may underlie aberrant endothelial proliferation in astrocytomas. Our findings are consistent with reports on the role of TAZ in angiogenesis in embryonic retina and brain tissues, which suggest a new therapeutic target for treatment of aggressive tumors.
TAZ and its transactivating factor, TEA domain (TEAD) family members, can directly drive mesenchymal differentiation of malignant gliomas (14) . Our previous study confirmed that in glioma cells, elevated expression of TAZ is crucial for tumor invasion and rapid growth (18) . Recently, Sakabe et al (4), Wang et al (8) , and Kim et al (11) contemporaneously reported that TAZ plays a vital role in brain and retinal angiogenesis. A characteristic of highly malignant gliomas is obviously blood vessel proliferation. Here, we verified in a large cohort of astrocytoma samples having different levels of malignancy that TAZ immunoreactivity is positively correlated with WHO malignant tumor grade and tumor microvessel density.
In a study of retinal neovascularization, Kim et al established that TAZ localized in the nuclei of cells at the vascular front of the developing retina, where a strong VEGF gradient toward the front was also present (11) . In another study of subcellular localization, Wang et al reported that TAZ affected VEGFR2 protein trafficking from the Golgi apparatus to the plasma membrane (8) . These results indicated that the VEGF/ VEGFR2 signaling pathway was critically associated with the activation of TAZ. Our results were consistent with these reports. We found here that TAZ immunoreactivity in human astrocytoma samples was closely associated with VEGFR2 immunoreactivity in astrocytoma endothelial cells, suggesting that the VEGFR2/TAZ signaling pathway is also crucial for angiogenesis in astrocytomas, and perhaps, in other tumors.
Angiogenesis comprises a series of morphogenic events, including sprouting at the vascular tips, branching, lumen formation, anastomoses, and remodeling to form a functionally perfused network. In such delicate and complex processes, several key ligands and their receptors, including VEGF/ VEGFR2, DLL4/Notch, angiopoietin/TIE2, Wnt/frizzled, PDGF/PDGFR, and cell matrix/integrin, are critical factors for normal angiogenesis, as reviewed by Potente et al (19) . Each of these pathways has been reported to be in crosstalk with the Hippo pathway and modulates YAP/TAZ activity in different cell types (20) . Therefore, TAZ can be considered to be an integration point in cells that can be triggered by multiple signals.
YAP/TAZ is speculated to mediate physiological functions by interacting with DNA-binding transcription factors. In addition to the TEAD family of transcription factors, YAP/ TAZ also interact with other transcription factors, including Smad, RUNX1/2, P63/P73, and ErbB417 (21) . YAP/TAZ regulates transcription via several mechanisms, including recruitment of general factors, modification of epigenetic markers, and modulation of chromatin structure (10) . Therefore, more in-depth study is required to determine whether other types of signaling molecules are involved in TAZ expression that further regulates angiogenesis related to glioma growth.
The role of VEGF in tumor angiogenesis has motivated various treatment strategies that specifically target these 2 molecules. Bevacizumab is a humanized IgG1 monoclonal antibody that selectively binds with high affinity to human VEGF and neutralizes the physiological activity of VEGF (22) . Although clinical trials demonstrate a prolonged progression-free survival of patients with bevacizumabtreated glioma, a benefit to overall survival has not yet been demonstrated (22) . Tumor resistance to therapies has several mechanisms. Those postulated to contribute to bevacizumab failure include promotion of tumor adaptation, promoting mesenchymal differentiation with increased invasiveness, and reactivating angiogenesis through the upregulation of other proangiogenic factors, and tumor invasion of normal brain areas (22) . Recently, Azard et al reported that VEGFR2 serves as a regulator of the Hippo pathway in angiogenesis (23) .
Notch, transforming growth factor b, bone morphogenetic protein, Wnt, and GPCR signaling pathways are also important for blood vessel development (24, 25) . Each of these pathways has been reported to be in crosstalk with the Hippo signaling pathway and to modulate YAP/TAZ activity in different cell types (20) . Wang et al pointed out that YAP/TAZ is a major nexus that converges and integrates different angiogenic stimuli to produce precise transcriptional programs in endothelial cells (8) . Porphyrin family molecules, especially verteporfin, can disrupt the interaction between YAP/TAZ and their transcription factors (26) . Another newly designed FIGURE 3. Continued also significantly higher than those of LGG samples. Plots of CBV and CBF of GBMs in 12 patients with paired blood perfusion measurements (before excision) and TAZ IRS values calculated from immunohistochemical staining of samples prepared after tumor excision. TAZ IRS did not correlate with CBV of the tumor (G) but was positively with tumor CBF (H), showing that degree of blood perfusion may be related to TAZ expression in the tumor vasculature. **p < 0.01; unpaired t-test was used for evaluating group differences. Scale bars: 50 lm. polypeptide, termed "super-TDU," is reported to suppress TAZ/YAP-TEAD interactions, which in turn retards tumor growth (27) .
In conclusion, inhibiting YAP/TAZ activity might offer a new and attractive antiangiogenesis strategy for treating aggressive astrocytomas. Progress on this front will depend on being able to spatially and selectively manipulate YAP/TAZ protein levels, an achievement that will be of great interest to neurologists, neurosurgeons, and basic neuroscientists.
